Clinical prognostic biomarkers in chronic lymphocytic leukemia and diffuse large B-cell lymphoma

Elizabeth C. Chastain, Eric J. Duncavage

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations

Abstract

Context. - Diffuse large B-cell lymphoma and chronic lymphocytic leukemia are 2 of the most common B-cell lymphomas in adults. Both diffuse large B-cell lymphoma and chronic lymphocytic leukemia share heterogeneous outcomes, and the use of prognostic biomarkers to better stratify risk in these patients has now become common-place. Objective. - To review chronic lymphocytic leukemia and diffuse large B-cell lymphoma biomarkers commonly used in the clinical laboratory, which can be divided into the following 3 main groups by testing methodology: chromosomal based (including fluorescence in situ hybridization and cytogenetics), expression based (including immunohistochemistry and flow cytometry), and DNA based (including gene sequencing for somatic mutations and IGVH mutational status). Data Sources. - Review of recent literature. Conclusions. - In chronic lymphocytic leukemia, important biomarkers include expression of CD38 and ZAP-70, IGVH mutational status, somatic mutations in TP53 and NOTCH1, and abnormalities in chromosomes 11, 12, 13q, and 17. In diffuse large B-cell lymphoma, important biomarkers include chromosomal rearrangement of BCL2, BCL6, and MYC and expression of CD5, BCL2, and CD43, as well as somatic mutations in TP53 and BCL6.

Original languageEnglish
Pages (from-to)602-607
Number of pages6
JournalArchives of Pathology and Laboratory Medicine
Volume139
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Dive into the research topics of 'Clinical prognostic biomarkers in chronic lymphocytic leukemia and diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this